PRODUCT NEWS
NEW INNOVATION FOR THE MANAGEMENT OF DRY EYE DISEASE
Scope Ophthalmics launches Tranquileyes™, a first-of-its-kind treatment for the management of meibomian gland dysfunction and dry eye disease – a condition affecting up to one in the 3 people aged over 65. Tranquileyes™ enables patients to create a moist-heat compress that effectively loosens the oils in the meibomian glands, helping to boost hydration and circulation.
Tranquileyes™ is available as: Instants (travel use), Beads (home use), and Advanced (hybrid). Price from £29.99 RRP. Available from Scope Ophthalmics, 0800 270 0253.
Ultibro® Breezhaler® ▼ (indacaterol/glycopyrronium bromide) launched in the UK for
the treatment of chronic obstructive pulmonary disease (COPD) Novartis’ Ultibro®
Breezhaler®▼ (indacaterol/glycopyrronium bromide), a once-
daily dual bronchodilator for the maintenance treatment of chronic obstructive pulmonary disease (COPD), has been launched by Pfizer in the UK
Data shows that Ultibro® Breezhaler® to current standard treatments.[2],[3]
,[4]
significantly improved lung function compared Patients receiving Ultibro®
Breezhaler® also
reported significant improvements in outcomes including breathlessness and use of rescue medication compared to open-label tiotropium 18 mcg and compared to salmeterol/fluticasone, in patients with no history of moderate or severe exacerbations over the last year.2,3,4
It is estimated that the direct cost of providing care in the NHS for people with COPD is almost £500 million a year – more than half of which relates to hospital care.1 COPD is the second most common cause of emergency hospital admissions and one of the most costly inpatient conditions treated by the NHS.1 References on request
ACTAVIS LAUNCHES NEWLY LICENSED PRODUCT ARIPIPRAZOLE
Actavis is launching Aripiprazole Conventional Tablets and Orodispersible Tablets.
Aripiprazole is used for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. It is also used for the treatment of moderate to severe manic episodes in Bipolar 1 Disorder and for the prevention of a new manic episode in adults who experience predominantly manic episodes and episodes which respond to Aripiprazole treatment.
Actavis will be supplying Aripiprazole in two different forms, Conventional Tablets 5mg, 10mg, 15mg and 30mg x 28 and Orodispersible Tablets 10mg and 15mg x 28.
All products are available through major wholesalers or directly from the Actavis Telemarketing team on Free Phone: 0800 731 0370 or fax: 0800 731 0380.
PRODUCT
Aripiprazole Conventional Tablets
Aripiprazole Orodispersible Tablets
STRENGTH
5mg 10mg 15mg 30mg
10mg 15mg
PIP CODE SIZE
120-0849 120-0864 120-0856 120-0831
120-0872 120-0880
28 28 28 28
28 28
COST
£76.83 £76.83 £76.83 £153.66
£96.04 £96.04
IMAGINE THIS: DIABETIC KIDS WITH IDEAL BLOOD GLUCOSE LEVELS. The world’s first motivational and Angry Birds™ themed MODZ blood glucose meter.
With MODZ, children will finally want to measure consistently and thus achieve improved blood glucose (BG) values. Points and rewards make measuring exciting and reminders help them to be consistent. Parents stay up-to-date with both e-mail and text message notifications and a web-based monitoring and analytics system.
MODZ is a motivational diabetes management system that consists of an Angry Birds™ themed blood glucose meter with a colour touch screen, MODZ measuring sticks and information management. Managing information with MODZ is easy: the blood glucose meter sends test results automatically as a text message to a mobile phone and wirelessly to MODZweb. MODZweb is a service on the Internet, where all test results and the carbohydrate contents of meals as well as sports exercises logged in the meter will be stored. There’s no need for wires or software, but you can find all information whenever you want with any device that has access to the Internet.
Smaller and lighter than a typical cell phone, MODZ is perfect for little hands and little pockets to carry around. It has a rechargeable battery, takes only five seconds to test and uses a small sample size.
FOR MORE INFORMATION
www.gomodz.com
AstraZeneca announced the UK launch of a new pre-filled pen for the administration of their once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist Bydureon® (exenatide once-weekly). Bydureon Pen 2mg is a pre-filled, single-use pen injector, which contains the same formulation and dose as the original exenatide once-weeklysingle-dose tray.
This is a significant development for both patients and clinicians, as the new pen eliminates the need for the patient to transfer the medication between a vial and syringe, simplifying administration of the injection. The pen can be administered at any time of the day, with or without meals and requires no titration.
Patients currently prescribed exenatide once-weekly in the single-dose tray will be transitioned onto the new pen by mid-2015, ensuring no interruption of treatment during this period. All newly prescribed patients will receive the exenatide once-weekly pen from January 2015 onwards.
The most common side effects seen with exenatide once-weekly treatment are mild to moderate, decrease over time, and mainly affect the stomach and gut (nausea, vomiting, diarrhoea and constipation). In addition, reactions at the site of injection (itching), low blood sugar levels (when used with a sulphonylurea) and headaches can occur.
For further information about exenatide once-weekly, including the full therapeutic indication, adverse reactions, precautions, contraindications and method of use, see the Summary of Product Characteristics (SPC) available at:
http://www.medicines.org.uk/emc/ medicine/24665/SPC/BYDUREON+2+mg+powder+and+solvent+for+pr olonged-release+suspension+for+injection/
References available on request SCOTTISH PHARMACIST - 51
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56